期刊,Journal of diabetes. 2022年14卷8期_国家学术搜索

期刊信息/Journal information

Journal of diabetes.

Blackwell Publishing Asia,

主办单位：Blackwell Publishing Asia,

国际刊号：1753-0393

Journal of diabetes./Journal Journal of diabetes.

正式出版

收录年代

Diabetes update: What's new, what's interesting

Bloomgarden, Zachary T.

3页

原文链接:

NSTL
Wiley

Glomerular cell cross talk in diabetic kidney diseases

Dong, RuixueXu, Youhua

10页

查看更多>>摘要：Diabetic kidney disease (DKD) is a severe microvascular complication of diabetes mellitus. It is the leading inducement of end-stage renal disease (ESRD), and its global incidence has been increasing at an alarming rate. The strict control of blood pressure and blood glucose can delay the progression of DKD, but intensive treatment is challenging to maintain. Studies to date have failed to find a complete cure. The glomerulus's alterations and injuries play a pivotal role in the initiation and development of DKD. A wealth of data indicates that the interdependent relationship between resident cells in the glomerulus will provide clues to the mechanism of DKD and new ways for therapeutic intervention. This review summarizes the significant findings of glomerular cell cross talk in DKD, focusing on cellular signaling pathways, regulators, and potential novel avenues for treating progressive DKD.

原文链接:

NSTL
Wiley

Impact of SARS-CoV2 on youth onset type 2 diabetes new diagnoses and severity

DeLacey, SeanArzu, JenniferLevin, LauraRanganna, Adesh...

9页

查看更多>>摘要：Introduction Initial reports show an increase in youth onset type 2 diabetes during the COVID-19 pandemic. We aim to expand on existing evidence by analyzing trends over a longer period. Objectives Our study aims to describe change in the amount, severity, and demographics of youth onset type 2 diabetes diagnoses during the COVID-19 pandemic compared to the five years before. Methods We performed a retrospective cross-sectional review of youth (age <= 21) diagnosed with type 2 diabetes during the COVID-19 pandemic (1 May 2020-30 April 2021) and the five years before (1 May 2015-30 April 2020) at a tertiary care center. Children were identified by International Classification of Diseases codes. Charts were reviewed to confirm diagnosis. Chi-square, t tests, and Fisher's exact tests were used for analyses. Results In the prepandemic era annual diagnoses of type 2 diabetes ranged from 41-69 (mean = 54.2), whereas during the pandemic period 159 children were diagnosed, an increase of 293%. The increase resulted in a higher incidence rate ratio during the pandemic than before, 2.77 versus 1.07 (p = .006). New diagnoses increased most, by 490%, in Non-Hispanic Black patients. The average HbA(1c) at presentation was higher during the pandemic (9.5% +/- 2.6) (79.9 mmol/mol +/- 28.2) than before (8.7%+/- 2.1) (72.1 mmol/mol +/- 23.1) (p = .003). Of those diagnosed during the pandemic, 59% were tested for COVID-19 and three tested positive. Conclusions New diagnoses of type 2 diabetes increased during the pandemic, most notably in Non-Hispanic Black youth. There was not a significant correlation found with clinical or biochemical COVID-19 infection in those tested.

原文链接:

NSTL
Wiley

Association between metabolic phenotype and urinary albumin-creatinine ratio in Chinese community adults: A cross-sectional study

Zhang, YueLi, BinqiLiu, YangGao, Wenxing...

10页

查看更多>>摘要：Background Urinary albumin-creatinine ratio (UACR) is a sensitive marker of kidney injury. This study analyzed the prevalence of different metabolic phenotypes and investigated their relationship with UACR in Chinese community adults. Methods This study involved 33 303 participants over 40 years old from seven centers across China. They were stratified into six groups according to their body mass index (BMI) and metabolic status: metabolically healthy normal weight (MHNW), metabolically healthy overweight (MHOW), metabolically healthy obesity (MHO), metabolically unhealthy normal weight (MUNW), metabolically unhealthy overweight (MUOW), and metabolically unhealthy obesity (MUO). Increased albuminuria was defined as a UACR >= 30 mg/g. Results The percentages of MHNW, MHOW, MHO, MUNW, MUOW, and MUO were 27.6%, 15.9%, 4.1%, 19.8%, 22.5%, and 9.6%, respectively. Multiple logistic regression analysis showed that the MHO group (odds ratio [OR] 1.205; 95% CI, 1.081-1.343), MUNW group (OR 1.232; 95% CI, 1.021-1.486), MUOW group (OR 1.447; 95% CI, 1.303-1.607), and MUO group (OR 1.912; 95% CI, 1.680-2.176) were at higher risk of increased albuminuria compared to the MHNW group. Subgroup analysis indicated that the risk of increased albuminuria was further elevated among regular smokers in men aged 40 to 55 years old with abdominal obesity. Conclusions Among Chinese community adults, increased albuminuria was associated with increased BMI whether metabolism was normal or not, and those with abnormal metabolism were at greater risk of increased albuminuria than those with normal metabolism. These findings suggest that overweight or obesity or metabolic abnormalities are risk factors for chronic kidney disease.

原文链接:

NSTL
Wiley

Xiaoketongbi Formula vs pregabalin for painful diabetic neuropathy: A single-center, randomized, single-blind, double-dummy, and parallel controlled clinical trial

Lu, QiyunChen, BenjianLiang, QingshunWu, Liyan...

11页

查看更多>>摘要：Background We assessed the efficacy and safety of the Xiaoketongbi Formula (XF) vs. pregabalin in patients with painful diabetic neuropathy (PDN). Methods Patients with PDN (n = 68) were included in a single-center, randomized, single-blind, double-dummy, parallel controlled clinical trial. The primary outcome was the change in the Brief Pain Inventory for Diabetic Peripheral Neuropathy (BPI-DPN). Secondary outcomes evaluated included the reduction of BPI-DPN >50%, changes in the numeric rating scale-11 (NRS-11) score for pain, Daily Sleep Interference Diary (DSID), Patient Global Impression of Change (PGIC), nerve conduction velocity (NCV), and adverse events. Results After 10 weeks of treatment, the BPI-DPN score reduced from 42.44 +/- 17.56 to 26.47 +/- 22.22 and from 52.03 +/- 14.30 to 37.85 +/- 17.23 in the XF and pregabalin group (P-s < 0.001), respectively. The difference in the absolute change in BPI-DPN score between both groups was -1.79 (95% CI: -9.09, 5.50; p = 0.625). In the XF and pregabalin groups, 44.1% (15/34) and 20.6% (7/34) of patients reported a BPI-DPN reduction >50% (p = 0.038), respectively. There were no significant differences between groups in NRS-11 and DSID (P-s > 0.05). A significantly greater number of patients in the XF group felt "significantly improved" or "improved" than in the pregabalin group (35.3% (12/34) vs. 11.8% (4/34), p = 0.045). The absolute change in motor nerve conduction velocity of the right median nerve was significantly different between both groups (XF group 0.7 +/- 2.3 vs. pregabalin group -2.2 +/- 4.1, p = 0.004). No serious adverse events were reported in either group. Conclusions XF is equivalent to pregabalin in reducing pain symptoms and improves the quality of life in patients with PDN. In addition, XF has the potential to improve nerve function by increasing NCV.

原文链接:

NSTL
Wiley

Increased incidence of childhood type 1 diabetes during the COVID-19 pandemic. Figures from an Italian tertiary care center

Schiaffini, RiccardoDeodati, AnnalisaRapini, NovellaPampanini, Valentina...

2页

查看更多>>摘要：Highlights In 2021 as a whole we report an increase (22% to 35%) in incidence of type 1 diabetes compared to the years 2017 to 2020. A peak of incidence in the last 4 months of 2021, when the "fourth wave" of COVID-19 peaked in Italy, has been observed. In the last quarter of 2021 there was a significant increased type 1 diabetes incidence in the age group under 12 years. We speculate that SARS-CoV-2 infection may have had an impact on type 1 diabetes incidence in children, especially in age groups not protected by vaccination.

原文链接:

NSTL
Wiley